UNSPSC 51202601: Ascomycin

This classification denotes an immunosuppressant and a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AUF4U5NSJK, chemically known as (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0?,?]octacos-18-ene-2,3,10,16-tetrone but more generally known as ascomycin, which bears US NIH Compound Identifier 5282071.

Most nations, for tariff and trade purposes, schedule ASCOMYCIN under HS 29349990 and SITC 51579. SMILES: CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)C.

UNSPSC 51202601 Ascomycin is a Commodity code that in recent state and local procurement shows no relevant activity. The two most recent opportunities tagged to this code — a pharmaceutical piggyback contract awarded by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems — involve different active pharmaceutical ingredients and do not align with ascomycin procurement. The code's abstract scope (ascomycin, an immunosuppressant macrolide used in transplant and dermatologic contexts) does not match the antibiotic and opioid-antagonist products actually being solicited under the code designation in current opportunities.

State and local buyers do not show measurable current demand under this code. Vendors evaluating pursuit should verify with issuing bodies whether ascomycin-specific opportunities exist outside the tagged records, as the present activity reflects classification mismatch rather than active procurement in this commodity line.